TABLE 2. Summary of efficacy conclusions and implications for clinical practice for limb tremor in ETa

| Pharmacological                        |                                                                 | Efficacy                                       | Implications<br>for Clinical       | Cafaby Canalysis ==                                                                                                                                                      |
|----------------------------------------|-----------------------------------------------------------------|------------------------------------------------|------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Class                                  |                                                                 | Conclusions                                    | Practice                           | Safety Conclusions                                                                                                                                                       |
| Anticonvulants                         | Carisbamate                                                     | Insufficient evidence                          | Investigational                    | Acceptable risk without specialized monitoring                                                                                                                           |
|                                        | Gabapentin                                                      | Insufficient evidence                          | Investigational                    | Acceptable risk without specialized monitoring                                                                                                                           |
|                                        | Levetiracetam                                                   | Nonefficacious                                 | Not useful                         | Acceptable risk without specialized monitoring                                                                                                                           |
|                                        | Pregabalin                                                      | Nonefficacious                                 | Not useful                         | Acceptable risk without specialized monitoring                                                                                                                           |
|                                        | Progabide                                                       | Unlikely efficacious                           | Unlikely useful                    | Acceptable risk without specialized monitoring                                                                                                                           |
|                                        | Topiramate                                                      | Efficacious                                    | Clinically useful                  | Acceptable risk without specialized monitoring                                                                                                                           |
|                                        |                                                                 | (>200 mg/day)                                  | (>200 mg/day)                      | The most common adverse effects with topiramate were appetite suppression, weight loss, cognitive impairment, an paresthesias.                                           |
|                                        | Zonisamide                                                      | Insufficient evidence                          | Investigational                    | Acceptable risk without specialized monitoring                                                                                                                           |
| Beta-lockers                           | Propranolol                                                     | Efficacious                                    | Clinically useful                  | Acceptable risk without specialized monitoring                                                                                                                           |
|                                        |                                                                 |                                                |                                    | Withdrawals were rare and mainly attributed to fatigue and bradycardia.                                                                                                  |
|                                        | Propranolol long-acting                                         | Insufficient evidence                          | Investigational                    | Acceptable risk without specialized monitoring                                                                                                                           |
|                                        | Nadolol                                                         | Insufficient evidence                          | Investigational                    | Acceptable risk without specialized monitoring                                                                                                                           |
|                                        | Metoprolol                                                      | Insufficient evidence                          | Investigational                    | Acceptable risk without specialized monitoring                                                                                                                           |
|                                        | Atenolol<br>Sotalol                                             | Insufficient evidence<br>Insufficient evidence | Investigational<br>Investigational | Acceptable risk without specialized monitoring Acceptable risk without specialized monitoring                                                                            |
| Barbiturates                           | Primidone                                                       | Efficacious                                    | Clinically useful                  | Acceptable risk with specialized monitoring  Acceptable risk with specialized monitoring                                                                                 |
| Dai Ditui ates                         | Tillilluolle                                                    | Lineacious                                     | Cirrically decidi                  | Consistent withdrawal attributed to adverse effects (first dose acute toxic reaction, sedation, daytime sleepiness, tiredness nausea, ataxia, dizziness, and confusion). |
|                                        | Phenobarbital/phenobarbitone                                    | Insufficient evidence                          | Investigational                    | Acceptable risk with specialized monitoring                                                                                                                              |
|                                        |                                                                 |                                                |                                    | Phenobarbital may be associated with depression and cognitive                                                                                                            |
|                                        |                                                                 |                                                |                                    | and behavioral effects.                                                                                                                                                  |
|                                        | T2000 (1,3-dimethoxymethyl-<br>5,5-dephenyl-barbituric<br>acid) | Insufficient evidence                          | Investigational                    | Insufficient evidence to make conclusions on the safety of the intervention                                                                                              |
| Benzodiazepines                        |                                                                 | Likely efficacious                             | Possibly useful                    | Acceptable risk with specialized monitoring                                                                                                                              |
|                                        | ·                                                               | ·                                              | ·                                  | Adverse effects with benzodiazepines include sedation, and cognitive and behavioral effects have been well described to ther conditions.                                 |
| Calcium<br>channel<br>blockers         | Flunarizine                                                     | Insufficient evidence                          | Investigational                    | Acceptable risk with specialized monitoring                                                                                                                              |
|                                        |                                                                 |                                                |                                    | Flunarizine been associated with the development of parkinsonism and other movement disorders. 15-19                                                                     |
|                                        | Nimodipine                                                      | Insufficient evidence                          | •                                  | Acceptable risk without specialized monitoring                                                                                                                           |
| Carbonic                               | Methazolamide                                                   | Insufficient evidence                          | Investigational                    | Acceptable risk with specialized monitoring                                                                                                                              |
| anhydrase<br>inhibitors<br>Other drugs |                                                                 |                                                |                                    | CBC and platelets should be measured before starting methazolamide and periodically during use to monitor for hematological reactions. Serum electrolytes should also be |
|                                        | Acetazolamide                                                   | Insufficient evidence                          | Unlikely useful                    | periodically monitored.  Acceptable risk with specialized monitoring                                                                                                     |
|                                        | Amantadine                                                      | Insufficient evidence                          | Investigational                    | Acceptable risk with specialized monitoring  Acceptable risk without specialized monitoring                                                                              |
| Outer drugs                            | Isoniazid                                                       |                                                | Unlikely useful                    | Unacceptable risk                                                                                                                                                        |
|                                        | Isomaziu                                                        | mounicient evidence                            | Officely decidi                    | Isoniazid can lead to severe and possibly fatal hepatitis.                                                                                                               |
|                                        | Mirtazapine                                                     | Insufficient evidence                          | Investigational                    | Acceptable risk without specialized monitoring                                                                                                                           |
|                                        | Olanzapine                                                      | Insufficient evidence                          | Investigational                    | Acceptable risk with specialized monitoring                                                                                                                              |
|                                        | ola leapine                                                     |                                                | ougusona.                          | Associated with the induction of parkinsonism, akathisia, and tardive dyskinesia                                                                                         |
|                                        | Theophylline                                                    | Insufficient evidence                          | Investigational                    | Acceptable risk without specialized monitoring                                                                                                                           |
|                                        | Trazodone                                                       | Unlikely efficacious                           | Unlikely useful                    | Acceptable risk without specialized monitoring                                                                                                                           |
| Botulinim toxin                        | Botulinum toxin type A                                          | Likely efficacious                             | Possibly useful                    | Acceptable risk with specialized monitoring                                                                                                                              |
| _                                      |                                                                 |                                                |                                    | Hand weakness was a frequent dose-related adverse event.                                                                                                                 |
| Surgery                                | Unilateral Vim-DBS                                              | Likely efficacious                             | Possibly useful                    | Acceptable risk with specialized monitoring                                                                                                                              |
|                                        | Bilateral Vim-DBS                                               | Insufficient evidence                          | Investigational                    | Acceptable risk with specialized monitoring                                                                                                                              |
|                                        | Unilateral Radiofrequency<br>thalamotomy                        | Likely efficacious                             | Possibly useful                    | Acceptable risk with specialized monitoring                                                                                                                              |
|                                        | Unilateral Gamma-knife<br>thalamotomy                           | Insufficient evidence                          | Investigational                    | Acceptable risk with specialized monitoring                                                                                                                              |
|                                        | Unilateral MRI-focused ultrasound thalamotomy                   | Likely efficacious                             | Possibly useful                    | Acceptable risk with specialized monitoring                                                                                                                              |

<sup>&</sup>lt;sup>a</sup>See further details in the Supporting Information. CBC, complete blood count.